← Retour à la une
Asie · Marchés régionaux · Vietnam Investment Review

Yicura BioMed completes first closing of Series B financing

Publié par Vietnam Investment Review · Vietnam il y a 16 h
Yicura BioMed completes first closing of Series B financing
Yicura BioMed completes first closing of Series B financing · Vietnam Investment Review

Résumé détaillé

Clinical-stage immunotherapy firm Yicura BioMed completed the first closing of its Series B funding round led by Gobi Partners on 13 November 2026 to advance its ICVAX HIV product.

HONG KONG SAR – Media OutReach Newswire – 13 November 2026 – Yicura BioMed ("Yicura"), a clinical-stage immunotherapy company based in the Hong Kong Science Park developing medicines for infectious diseases, cancers, and inflammatory diseases, is pleased to announce today the first closing of its Series B financing led by Gobi Partners, with participation from a number of strategic investors from Wuxi and institutional investors from Hong Kong. Their participation reflects shared confidence in Yicura's clinical development path.

The issuer is solely responsible for the content of this announcement.

Début de l'article, extrait de Vietnam Investment Review. Pour lire la suite, ouvrez l'article chez le média.

Lire l'article complet sur Vietnam Investment Review Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (vir.com.vn)

À lire aussi